IASIS PHARMA is pleased to announce the launch of the new 60 f.c. tabs packaging for GLUCOPLUS® 1.000mg (Metformin hydrochloride). Both GLUCOFREE® & GLUCOPLUS® (active ingredient: metformin hydrochloride) belong to the broader category of Oral Hypoglycemic Agents (OHAs) for the treatment of Type 2 Diabetes Mellitus (T2D) as first-line therapy. GLUCOFREE® is available in 850mg metformin hydrochloride, [...]
IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Sensibio® in 30 g. new package. Sensibio® 30 g. new package was launched to the market in order to complete Sensibio® 15 g., the well-established fixed combination of Fusidic acid (antibiotic) and [...]
IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Flusterix® in 30 g. new package. Flusterix® 30 g. was launched in order to complete the, well-established to the pharmaceutical market, Flusterix® 15 g. package. Flusterix® has Fusidic acid as its active ingredient, [...]
IASIS PHARMA proudly announces the addition of Glucofree® & Glucoplus® to its wide product portfolio. Glucofree® & Glucoplus® have metformin hydrochloride as their active ingredient and they belong to OHAs (Oral Hypoglycemic Agents). Metformin’s therapeutic indication is type 2 diabetes, especially on obese patients when the imposed diet and body exercise are not enough to [...]
IASIS PHARMA announces the launch of MAG-IASIS®, the first uniquely effective combination indicated for magnesium deficiency in the form of effervescent tablets. Each effervescent tablet of MAG-IASIS® contains: 1193.57 mg magnesium citrate & 667.56 mg magnesium aspartate equivalent to 243 mg Magnesium. MAG-IASIS® main indications are: ● magnesium deficiency, under the condition that it cannot [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name of ZALEPIN® RAPID, enriching its CNS product portfolio. ZALEPIN® RAPID contains Olanzapine as its active ingredient and belongs to the class of atypical antipsychotic agents, the newer generation of antipsychotics. ZALEPIN® RAPID is available in the form of orodispersible tablets (ODT), offering the [...]
IASIS PHARMA announces the launch of the original antihypertensive pharmaceutical product under the brand name of Rami-Amlo®. The product is a fixed-dose combination of an Angiotensin Converting Enzyme (ACE) Inhibitor with a Calcium Channel Blocker. Each Rami-Amlo® capsule, contains the active ingredients Ramipril & Amlodipine, combined in a single dosage form, in 4 strengths: 5mg [...]
IASIS PHARMA consistently aware of its responsibility to serve at the highest possible level the health care professionals and the patients is introducing in the pharmaceutical market the new pack of 30 caps of Relief® in order to fully comply with the Greek and International Guidelines. Relief® caps BTx30 pack size is an important addition [...]
Pharma Q, a member of IASIS PHARMA group of companies, has launched a new pharmaceutical product under the brand name Licosil (Sildenafil) to treat erectile dysfunction. Licosil is the 1st generic sildenafil, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical industry in τwο strengths: 50 and 100 mg respectively [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name Lartokaz. It is an Irbesartan/hydrochlorothiazide combination preparation in two strengths: (150+12,5)mg/tab and (300+12,5)mg/tab respectively. Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension and in a combination formulation with hydrochlorothiazide(diuretic), is able to achieve an additive antihypertensive effect.
